



Rexahn Pharmaceuticals, Inc.
Investor Relations Department
15245 Shady Grove Road, Suite
455
Rockville, MD 20850
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

AMEX: RNN

Last Trade:	2.08
Trade Time:	8:00 PM ET 11/17/17
Change:	-0.06 ↓ (2.804%)
Day Range	2.05 - 2.19
52-Week Range	1.27 - 7.10
Volume	317,869


Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 11/09/17 [Rexahn Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference](#)
- 11/08/17 [Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Clinical Trial of RX-3117 in Combination with Abraxane® in Patients Newly Diagnosed with Metastatic Pancreatic Cancer](#)
- 11/06/17 [Rexahn Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update](#)
- 10/13/17 [Rexahn Announces \\$8 Million Registered Direct Offering](#)
- 10/10/17 [Rexahn Pharmaceuticals Receives Positive Opinion from European Medicines Agency for Orphan Drug Designation for RX-3117](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- 02/24/17 [Annual Report \(10-K\)](#)
- 02/24/17 [Proxy Statement \(DEF 14A\)](#)
- 11/03/17 [Quarterly Report \(10-Q\)](#)
- 08/04/17 [Quarterly Report \(10-Q\)](#)
- 05/03/17 [Quarterly Report \(10-Q\)](#)